JP2024511387A5 - - Google Patents

Info

Publication number
JP2024511387A5
JP2024511387A5 JP2023557128A JP2023557128A JP2024511387A5 JP 2024511387 A5 JP2024511387 A5 JP 2024511387A5 JP 2023557128 A JP2023557128 A JP 2023557128A JP 2023557128 A JP2023557128 A JP 2023557128A JP 2024511387 A5 JP2024511387 A5 JP 2024511387A5
Authority
JP
Japan
Prior art keywords
acc
optionally
monomer
construct
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020492 external-priority patent/WO2022197764A2/en
Publication of JP2024511387A publication Critical patent/JP2024511387A/ja
Publication of JP2024511387A5 publication Critical patent/JP2024511387A5/ja
Pending legal-status Critical Current

Links

JP2023557128A 2021-03-16 2022-03-16 マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 Pending JP2024511387A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16
US63/161,913 2021-03-16
US202163164827P 2021-03-23 2021-03-23
US63/164,827 2021-03-23
US202163254748P 2021-10-12 2021-10-12
US63/254,748 2021-10-12
US202163276893P 2021-11-08 2021-11-08
US63/276,893 2021-11-08
PCT/US2022/020492 WO2022197764A2 (en) 2021-03-16 2022-03-16 Masked activatable cytokine constructs and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2024511387A JP2024511387A (ja) 2024-03-13
JP2024511387A5 true JP2024511387A5 (cg-RX-API-DMAC7.html) 2025-03-24

Family

ID=81389111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557128A Pending JP2024511387A (ja) 2021-03-16 2022-03-16 マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法

Country Status (11)

Country Link
US (2) US11667687B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308594A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024511387A (cg-RX-API-DMAC7.html)
KR (1) KR20230157448A (cg-RX-API-DMAC7.html)
AU (1) AU2022237504B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023018735A2 (cg-RX-API-DMAC7.html)
CA (1) CA3211924A1 (cg-RX-API-DMAC7.html)
IL (1) IL305716A (cg-RX-API-DMAC7.html)
MX (1) MX2023010840A (cg-RX-API-DMAC7.html)
TW (1) TW202304958A (cg-RX-API-DMAC7.html)
WO (1) WO2022197764A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
MX2024004301A (es) * 2021-10-08 2024-04-26 Cytomx Therapeutics Inc Construcciones de citocinas activables y metodos combinados.
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN119234000B (zh) * 2023-09-25 2026-04-17 深圳湾实验室 可激活穿膜构建体和降解子
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
GB0100551D0 (en) 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CN101184771A (zh) 2005-05-26 2008-05-21 先灵公司 干扰素-IgG融合体
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
WO2009079837A1 (en) 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
CN112351946B (zh) 2018-06-21 2022-07-08 Tgw物流集团有限公司 货仓及拣选系统和用于从悬挂袋和其他装载辅助器具中拣选订单货物的方法
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3114179A1 (en) * 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020123980A1 (en) 2018-12-14 2020-06-18 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
AU2020285636A1 (en) 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
KR20260089650A (ko) 2019-07-12 2026-06-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
AU2020316002B2 (en) 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021113577A1 (en) 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
AU2020403148A1 (en) 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US20240043489A1 (en) 2020-01-15 2024-02-08 Trutino Biosciences Inc. Cytokine Prodrugs Comprising a Cleavable Linker
MX2022011676A (es) 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
US20230226202A1 (en) 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
PH12022552627A1 (en) 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-2 cytokines and their cleavage products
PH12022552630A1 (en) 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
CA3178657A1 (en) 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof

Similar Documents

Publication Publication Date Title
US8669350B2 (en) TNF receptor Fc fusion proteins and in vivo methods of use
US12054530B2 (en) Immunomodulatory fusion proteins
US8333963B2 (en) Method of inhibiting osteoclast activity
US7790684B2 (en) Method of inhibiting osteoclast activity
US7666622B2 (en) Monomeric self-associating fusion polypeptides and therapeutic uses thereof
Seckinger et al. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor.
CN101146818B (zh) 生产分泌性三聚受体类似物和生物活性融合蛋白的方法与组合物
JP2023520517A5 (cg-RX-API-DMAC7.html)
Ashkenazi et al. Immunoadhesins as research tools and therapeutic agents
JP2020508691A5 (cg-RX-API-DMAC7.html)
EP4284819A1 (en) Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
US20030187224A1 (en) Chimeric OPG polypeptides
AU2009266863A1 (en) TNF-alpha antagonist multi-target being proteins
US20240052016A1 (en) Human il-10 receptor alpha fusion proteins
JPH08507676A (ja) 可溶性オリゴマー蛋白質の調製法
WO2005072340A2 (en) Novel polynucleotides encoding polypeptides and methods using same
US20250206794A1 (en) TGF-Beta Polypeptides
WO2022057909A1 (zh) 双特异性重组蛋白及其用途
WO2021052152A1 (zh) 二聚体免疫粘附素、药物组合物和用途
JP2025508882A5 (cg-RX-API-DMAC7.html)
JP2024538706A5 (cg-RX-API-DMAC7.html)
Aggarwal et al. Human tumour necrosis factors: structure and receptor interactions
JP2014124186A (ja) 多価抗体フラグメントおよびその三量体化複合体
RU2009126545A (ru) МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН
JP2024527629A5 (cg-RX-API-DMAC7.html)